Japan Study: MiniMed 780G Upgrade Cuts A1C & Daily Alarms

Japanese Researchers Measure Real-World Benefits of Upgrading to the MiniMed 780G

A study from Japan published in the Journal of Diabetes Investigation offers one of the first close looks at what actually happens when adults with type 1 diabetes upgrade from the MiniMed™ 770G® to the newer MiniMed™ 780G® system — and the results point to meaningful improvements in blood sugar control, device burden, and emotional well-being.

The research comes from the Department of Endocrinology and Diabetes at Yokohama City University Medical Center, where 21 adults were followed for three months after making the switch.

What Makes This Study Unique

Most insulin pump studies in the US focus on starting pump therapy from scratch or switching between brands. This Japanese team zeroed in on a more specific and increasingly common real-world scenario: upgrading within the same device family. Because Japan and the US share access to the same Medtronic MiniMed platform, these findings are unusually applicable to American patients — more so than many international studies that involve medications or devices not yet available in the US.

What the Researchers Found

• A1C dropped by 0.5% — from 7.5% to 7.0% on average. (A1C is the standard 3-month blood sugar average used in both Japan and the US.)
• Time in Tight Range (TITR) — the percentage of time glucose stayed between 70–140 mg/dL (3.9–7.8 mmol/L) — trended upward from about 45% to 49%, though this did not reach full statistical significance.
• Daily alarms dropped dramatically — from nearly 12 per day down to about 7. That's a reduction of roughly 4–5 fewer interruptions every single day.
• Manual sensor calibrations fell sharply — from 3.6 times per day to less than once per day, reducing the fingerstick burden on patients.
• Diabetes-related emotional distress improved — measured by the PAID (Problem Areas in Diabetes) questionnaire, scores dropped from 38.7 to 31.7, suggesting patients felt less overwhelmed by managing their condition, though this trend also narrowly missed statistical significance.

How This Compares to US Guidelines

The American Diabetes Association (ADA) recommends a target A1C below 7% for most adults with type 1 diabetes. The average A1C in this study reached exactly 7.0% after the upgrade — right at the guideline threshold. The ADA also recognizes diabetes distress as a critical, often underaddressed part of diabetes management, making the PAID score improvement especially relevant for US clinicians and patients.

Important Limitations to Know

This was a small study — just 21 participants at a single center in Japan — and it ran for only three months without a control group for comparison. The improvements in Time in Tight Range and emotional distress did not reach full statistical significance, meaning they should be viewed as encouraging trends rather than confirmed findings. Larger, longer studies are needed.

Why This Matters for US Patients

If you're currently using the MiniMed 770G in the US and considering an upgrade, this Japanese study suggests the 780G may offer real daily-life improvements — fewer alarms waking you at night, fewer fingersticks, and potentially better blood sugar numbers. Fewer alarms also means less sleep disruption, which itself affects blood sugar regulation. For anyone managing type 1 diabetes, reducing device burden while improving control is a meaningful quality-of-life win.

Managing type 1 diabetes with advanced technology still requires the right supplies at the right time. MDS Diabetes (mdsdiabetes.com) specializes in helping patients access the continuous glucose monitoring and insulin pump supplies they need — so your device can do its job without interruption.

Citation

Akiyama, Orime, Akamatsu (2026). Efficacy of MiniMed™ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed™ 770G®: A 3-month prospective single-center observational study. Journal of Diabetes Investigation. PMID: 41292258. DOI: 10.1111/jdi.70198. Country of Origin: Japan — Yokohama City University Medical Center, Yokohama, Japan.